An in silico evaluation of the ADMET profile of the StreptomeDB database

SpringerPlus

Volumn 2, Issue 1, 2013, Pages 1-11

  Ntie Kang, Fidele ^a,b,c  

^a UNIVERSITY OF BUEA   (Cameroon)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF DOUALA   (Cameroon)

Author keywords

3D structures; Database; In silico; Natural products; Streptomyces; Virtual screening

Indexed keywords

EID: 84887266301     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-2-353     Document Type: Article

References (51)

1. Ajay, Bermis GW, Murkco MA (1999) Designing libraries with CNS activity. J Med Chem 42:4942-4951.
2. Aronov AM (2005) Predictive in silico modeling for hERG channel blockers. Drug Discov Today 10:149-155.
3. Button WG, Judson PN, Long A, Vessey JD (2003) Using absolute and relative reasoning in the prediction of the potential metabolism of xenobiotics. J Chem Inf Comput Sci 43:1371-1377.
4. + channel blockers. J Med Chem 45:3844-3853.
5. + channels: spike-frequency adaptation. J Physiol 501:313-318.
6. Colmenarejo G, Alvarez-Pedraglio A, Lavandera J-L (2001) Cheminformatic models to predict binding affinities to human serum albumin. J Med Chem 44:4370-4378.
7. Cronin MTD (2003) Computer-assisted prediction of drug toxicity and metabolism in Modern Methods of Drug Discovery. In: Hillisch A, Hilgenfeld R (eds) Modern methods of drug discovery. Birkhäuser, Basel.
8. Cruciani C, Crivori P, Carrupt PA, Testa B (2000) Molecular fields in quantitative structure-permeation relationships: the VolSurf approach. J Mol Struc-Theochem 503:17-30.
9. Darvas F, Keseru G, Papp A, Dormán G, Urge L, Krajcsi P (2002) In Silico and Ex silico ADME approaches for drug discovery. Top Med Chem 2:1287-1304.
10. De Ponti F, Poluzzi E, Montanaro N (2001) Organising evidence on QT prolongation and occurrence of Torsades de Pointes with nonantiarrhythmic drugs: a call for consensus. Eur J Clin Pharmacol 57:185-209.
11. Di Masi JA, Hansen RW, Grabowsk HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22:151-185.
12. Duffy EM, Jorgensen WL (2000) Prediction of properties from simulations: free energies of solvation in hexadecane, octanol, and water. J Am Chem Soc 122:2878-2888.
13. Feher M, Schmidt JM (2003) Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J Chem Inf Comput Sci 43:218-227.
14. Gleeson MP, Hersey A, Hannongbua S (2011) In-silico ADME models: a general assessment of their utility in drug discovery applications. Curr Top Med Chem 11(4):358-381.
15. Greene N, Judson PN, Langowski JJ (1999) Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. SAR QSAR Environ Res 10:299-314.
16. Hansch C, Leo A, Mekapatia SB, Kurup A (2004) QSAR and ADME. Bioorg Med Chem 12:3391-3400.
17. Hedley PL, Jørgensen P, Schlamowitz S, Wangari R, Moolman-Smook J, Brink PA, Kanters JK, Corfield VA, Christiansen M (2009) The genetic basis of long QT and short QT syndromes: A mutation update. Human Mutation 30:1486-1511.
18. Hodgson J (2001) ADMET-turning chemicals into drugs. Nature Biotechnology 19:722-726.
19. Hou T, Wang J (2008) Structure-ADME relationship: still a long way to go? Expert Opin Drug Metab Toxicol 4(6):759-770.
20. Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR (1999) MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J Pharm Sci 88:28-33.
21. Jorgensen WL, Duffy EM (2000) Prediction of drug solubility from Monte Carlo simulations. Bioorg Med Chem Lett 10:1155-1158.
22. Jorgensen WL, Duffy EM (2002) Prediction of drug solubility from structure. Adv Drug Deliv Rev 54:355-366.
23. Jorgensen WL, Tirado-Rives J (1988) The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. J Am Chem Soc 110(6):1657-1666.
24. Jorgensen WL, Maxwell DS, Tirado-Rives J (1996) Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 118(45):11225-11236.
25. Kelder J, Grootenhuis PD, Bayada DM, Delbresine LP, Ploemen JP (1999) Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res 16:1514-1519.
26. Lhasa L (2010) Meteor, version 13.0.0. Lhasa, Leeds, UK.
27. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 23:3-25.
28. Lombardo F, Gifford E, Shalaeva MY (2003) In silico ADME prediction: data, models, facts and myths. Mini Rev Med Chem 3:861-875.
29. Lucas X, Senger C, Erxleben A, Grüning BA, Döring K, Mosch J, Flemming S, Günther S (2013) StreptomeDB: a resource for natural compounds isolated from Streptomyces species. Nucleic Acids Res 47:D1130-D1136.
30. Luco JM (1999) Prediction of brain-blood distribution of a large set of drugs from structurally derived descriptors using partial least squares (PLS) modelling. J Chem Inf Comput Sci 39:396-404.
31. Navia MA, Chaturvedi PR (1996) Design principles for orally bioavailable drugs. Drug Dev Today 1:179-189.
32. Ntie-Kang F, Mbah JA, Mbaze LM, Lifongo LL, Scharfe M, Ngo Hanna J, Cho-Ngwa F, Amoa Onguéné P, Owono Owono LC, Megnassan E, Sippl W, Efange SMN (2013) CamMedNP: Building the Cameroonian 3D structural natural products database for virtual screening. BMC Complement Altern Med 13:88.
33. OCHEM A platform for the creation of in silico ADME/Tox prediction models., http://www.eadmet.com/en/ochem.php.
34. Oprea TI (2002) Current trends in lead discovery: are we looking for the appropriate properties? J Comput-Aided Mol Des 16:325-334.
35. Potts RO, Guy RH (1992) Skin permeability. Pharm Res 9:663-669.
36. Potts RO, Guy RH (1995) A predictive algorithm for skin permeability: The effects of molecular size and hydrogen bond activity. Pharm Res 12:1628-1633.
37. Quinn RJ, Carroll AR, Pham MB, Baron P, Palframan ME, Suraweera L, Pierens GK, Muresan S (2008) Developing a drug-like natural product library. J Nat Prod 71:464-468.
38. Schneider G (2002) Trends in virtual computational library design. Curr Med Chem 9:2095-2102.
39. Schrödinger (2011a) QikProp, version 3.4. LLC, New York, NY.
40. Schrödinger (2011b) LigPrep software, version 2.5. LLC, New York, NY.
41. Schrödinger (2011c) Maestro, version 9.2. LLC, New York, NY.
42. Schrödinger (2011d) QikProp 3.4 User Manual. LLC, New York, NY.
43. Shivakumar D, Williams J, Wu Y, Damm W, Shelley J, Sherman W (2010) Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field. J Chem Theory Comput 6:1509-1519.
44. Stenberg P, Norinder U, Luthman K, Artursson P (2001) Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem 44:1927-1937.
45. Teague SJ, Davis AM, Leeson PD, Opea TI (1999) The design of leadlike combinatorial libraries. Angew Chem, Int Ed 38:3743-3748.
46. Tetko IV, Bruneau P, Mewes H-W, Rohrer DC, Poda GI (2006) Can we estimate the accuracy of ADMET predictions? Drug Discov Today 11:700-707.
47. Van de Waterbeemd H, Gifford E (2003) ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov 2:192-204.
48. + channels: Friend or foe. Trends Pharmacol Sci 22:240-246.
49. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45:2615-2623.
50. Verdonk ML, Cole JC, Hartshorn ML, Murray CW, Taylor RD (2003) Improved protein-ligand docking using GOLD. Proteins 52:609-623.
51. Yazdanian M, Glynn SL, Wright JL, Hawi A (1998) Correlating partitioning and caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res 15:1490-1494.